In addition to the well-recognised link between DSG2 mutation and cardiomyopathy in humans, a second clinical manifestation linked to DSG2 loss-of-function has been identified in patients with systemic sclerosis (SSc, scleroderma). Here, DSG2 is linked to scleroderma.